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Executive Summary 
With the decreasing cost of monoclonal antibody production, radioimmunotherapy (RIT) 
has rapidly emerged as one of the more promising methods of treating cancer cells.  RIT makes 
use of radio-labeled monoclonal antibodies to detect and deliver controlled doses of radiation to 
malignant cells.  The primary advantage of this method is that damage to normal, healthy tissue 
is minimized.  We investigated the use of radio-labeled antibodies as a method of tumor 
destruction. Our primary interests were the rate of antibody diffusion into the tumor, the antibody 
binding kinetics, and the overall effectiveness of radioimmunotherapy given the rate of 
radioactive decay.  By modeling the concentration of bound antibody with respect to time, we 
were able to optimize tumor destruction while minimizing the damage to the surrounding tissue.  
Our results show that a computer simulation using FIDAP is a time-saving, cost-effective 
method of obtaining quantitative results about the binding kinetics of antibody to tumor.  In 
addition, we determined that while the binding specificity plays an important role in ensuring 
proper binding to the tumor, the rate of antibody to antigen complex formation does not affect 
the treatment and that this process is limited by diffusion. Given this fact, we recommend that 
low molecular weight antibodies be used because they will typically have higher diffusivities.  In 
an example case of metastatic melanoma, we found that 4.33 mg of 
188Re-6D2 complex would 
destroy the tumor in our model. 
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Introduction 
 
Monoclonal antibodies (mAb) can be very useful in the delivery of drugs and treatment 
of solid tumors.  One such application is the delivery of an antibody conjugated with a 
radionuclide into a tumor.  A tumor-specific monoclonal antibody labeled with a radionuclide is 
delivered via an intravenous injection.  The antibody then diffuses through a layer of normal 
tissue and into the tumor.  Once inside the tumor, the antibody binds to tumor-associated 
antigens.  Since the monoclonal antibodies are highly specific to the tumor antigens, they will 
bind only with antigens in the tumor, thus localizing the radioactive rays and reducing the 
damage done to the surrounding tissue.   
  Using FIDAP we modeled the diffusion and binding of the monoclonal antibody through 
the normal tissue and into the tumor.  By modeling we are able to learn more about the kinetics 
and behavior of the binding process.  We are also able to determine a timeline for treatment and 
the optimum treatment dosage, as well as investigate the feasibility of actually using this method 
of treatment to destroy tumors. 
  The following report details the assumptions and conditions used to make our model and 
the process of solving it using FIDAP. Our results are reported and analyzed in addition to our 
conclusions and recommendations for an equivalent treatment that could be used. 
 
Design Objectives 
We had three major design objectives: 
1)  Model the diffusion of the monoclonal antibody through the normal tissue and the tumor 
2)  Model the binding of antibody to antigen using Michaelis-Menton parameters 
  23)  Based on the diffusion/binding behavior and considering radioactive decay, determine 
how much radioactivity must be injected for effective treatment of the tumor 
 
To do this we first assumed the tumor to be a sphere 0.03 cm in diameter as specified in 
literature
1.  The tumor was surrounded by a layer of normal tissue modeled as a sphere 0.3 cm in 
diameter.  We used axisymmetric geometry to model this process since it could be assumed that 
the diffusion and reaction occured symmetrically throughout the tumor and surrounding normal 
tissue.  In GAMBIT our mesh was a quarter of a circle with edges that were the length of the 
radius of the tumor and tissue.  The axis of symmetry was about the bottom edge, as shown 
below in Figure 1. 
 
Figure 1.  Schematic of tumor and tissue model (figure not to scale) 
   
 
 
  3Governing Equations in Appendix A 
In the normal tissue, diffusion is modeled using the diffusion equation: 
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where      cA = mAb concentration 
   D tis = tissue diffusivity 
In the tumor, terms for the reaction must be added into the diffusion equation: 
 
cs k cs k c
r r r
D
t
t r c
r f A tum
A + − ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
∂
∂
+
∂
∂
=
∂
∂ 2 ) , (
2
2
      (2) 
where       s = concentration of antigen(Ag) not bound to mAb 
      cs = concentration of mAb-Ag complex 
   kf,  kr  =  rate  constants  for forward and reverse reactions 
Dtums = tumor diffusivity 
 
The equation governing the reaction of antibodies and antigens is: 
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where      n = 2 is the binding valance of mAb 
   so = total Ag 
  4Boundary Conditions 
The concentration of antibody at the outer surface of the normal tissue varies to simulate 
the decrease in antibody concentration due to removal by the kidney.  This concentration change 
at the boundary is modeled with the following equation
1: 
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where λ, α = plasma kinetic parameters (see Appendix B) 
At one edge of the geometry there is a no flux boundary condition and at the other edge there is 
an axis of symmetry which both follow these equations: 
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At the tissue-tumor interface, the flux and the concentrations of the antibody are equal.  
However, there is a no flux boundary condition for the antigen and complex since they are bound 
to the tumor cells: 
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  5Initial Conditions 
Antibody concentrations are initially 0 nM throughout the tumor and tissue.  Antigen 
concentration has an initial value only within the tumor, which is initially considered 
homogeneous.  The mAb-Ag complex concentration is initially 0 nM throughout the tumor and 
tissue as well. 
cA  =   0   n M     f o r   a l l   r           ( 1 4 )  
s = so for r = 0  to r = rtum         ( 1 5 )  
c s   =   0   n M   f o r   a l l   r           ( 1 6 )  
 
See Appendix A for information regarding non-dimensionalization of the model. 
 
Mesh Formation 
  Using GAMBIT, a model mesh was made that included the tissue surrounding the tumor. 
This mesh, shown in Figure 2 contained three nodes of particular interest. They are circled and 
labeled in both Figures 2 and 3; note the distinction between the node called tumor “middle” and 
the tumor “center” node. 
 
  6
 
 
 
 
 
 
Figure 3. Close-up of tumor mesh with three nodes of interest: 
tumor surface, tumor “middle,” and tumor “center.”  Figure 2. Entire tissue/tumor model mesh. Results and Discussion 
 
Before manipulating any parameters, it was imperative to demonstrate that the model was 
running and the expected diffusion profile of the antibody (species 1) through the normal tissue 
was observed (Figures 4 and 5 below).  
  7
Figure iffusion of antibody (species 1) at the start of the
simulation.  
 4. D Figure 5. Diffusion of antibody at the end of the simulation.          
   
The total specified run-time of this simulation was 10 days and as expected, the antibody 
uniformly diffused into the tumor through the tissue.  However, the simulation would not run 
longer than approximately 3 days. 
The following plots, Figures 6 and 7, 
display the concentration profiles of antigen 
(species 2) and Ag-Ab complex (species 3), 
respectively, at the surface of the tumor (node 
821).  The antigen concentration began at 
1000 nM and decreased as antibody reached  
Figure 6. Decreasing concentration of antigen (species 2) over
time at the tumor surface.      8
Figure 8. Increasing concentration of Ab-Ag complex over
time near tumor middle.   
Figure 7. Increasing concentration of Ab-Ag complex (species 
3) over time at the tumor surface.   
the tumor and the complex was formed, thus increasing the concentration of complex from 0 nM 
to approximately 530 nM at the end of the simulation. These plots reveal the trend of antigen 
depletion as well as the antibody-antigen complex formation we anticipated. Figure 8 shows the 
increasing concentration of Ab-Ag complex near the tumor middle (node 971). In comparison to 
Figure 7, there is a greater time lag before the generation of Ab-Ag complex in the middle of the 
tumor as expected, which reflects the time necessary for the antibody to diffuse further into the 
tumor (while the overall pattern looks similar, the concentrations vary by a factor of almost ten). 
In examining the antibody diffusion through normal tissue and into the pre-vascular 
tumor we also analyzed the effects of changes to diffusivity, antigen concentration in the tumor, 
and the forward rate constant in the reaction forming the Ab-Ag complex.  Finally, we compared 
our original solution to those obtained from two different mesh designs.   
 
 
 
 
 Sensitivity Analysis 
Changing Diffusivity Values 
Once it was clear that the simulation was working as expected, we tested the effect of 
increasing the diffusivity values.  We observed that the initial penetration of antibody into the 
tissue at the start of the simulation was to a greater depth, and there was an overall decrease in 
the time taken for the antibody to diffuse into the tumor as anticipated (Figure 9).  
 
 Figure 10.  Decreasing concentration profile of antigen using
high diffusivity in response to complex formation at the tumor
surface. 
   
     
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 9.  Concentration contour of antibody using high
diffusivity. Contour reaches this state faster than in Figure 5.
 
The amount of free antigen shown in Figure 10 approached zero faster when using the high 
diffusivity than in Figure 6 with normal diffusivity.  Furthermore, Figures 11 and 12 show the 
generation of Ab-Ag complex and, when compared to earlier results in Figures 7 and 8, 
respectively, the formation of the complex is accelerated using higher diffusivity values for the 
antibody. 
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Figure 12.  Generation of Ab-Ag complex near tumor middle
using high diffusivity. Compare to Figure 8. 
Figure 11.  Generation of Ab-Ag complex at the tumor surface
using h gh diffusivity. Compare to Figure 7.   i  
Changing the antigen concentration 
Next, we were interested in determining what effect varying the concentration of antigen 
in the tumor would have on our model.  The control simulation previously discussed used an 
antigen concentration of 1000 nM, which we subsequently compared to simulations of 10, 100, 
and 10,000 nM.  Changes to the antigen concentration had no effect on the diffusion of antibody 
through the tissue at the start of the simulation (see Figures 13, 14, and 15 in Appendix C) as 
expected.  However, the contours at the end of the simulation were markedly different (see 
Figures 16, 17, and 18 in Appendix C), but this was due to the fact that the simulation ran for 
different times.  Figures 17 and 18 ran longer than 16, but when viewed at a time common to all 
three the concentration contours were the same.  Thus, we conclude that the diffusion of antigen 
through the tissue was not affected by variations in the concentration of antigen.   
The antigen concentration plots over time for the each of the 10, 100 and 10,000 nM 
concentrations are included in Appendix C as Figures 19, 20, and 21, respectively.  The trends 
show, as expected, that the shape of the curves overall are similar and that as initial concentration 
of antigen increased the time for total depletion increased.  In addition, changing the concentration of antigen affected the rate of Ab-Ag complex formation (see Figures 22 through 
27 in Appendix C) at the tumor surface and the tumor middle.  Both at the tumor surface and 
within the tumor (Appendix C: Figures 22-24 and Figures 25-27, respectively), show that 
complex formation at different Ag concentrations occurred at non-dimensional time 0.0083 for 
all plots at the surface and at the same non-dimensional time, 0.0088 within the tumor.  This time 
difference was approximately 1 hour of normal time. The dramatic increase in complex 
concentration (seen in each simulation) took place over the same duration when the 
concentration of available Ag increased, but as Ag concentration increased more time was 
required to bind all of that available Ag.   
 
Changing the Rate Constant 
We decreased the forward rate constant, kf, by a power of 10 which increased the amount 
of time the simulation actually ran to almost six and a half days (non-dimensional time 0.07728). 
This allowed us to observe the behavior of the reaction to a greater extent, as in Figure 28. 
Consequently, the rate of complex formation is 
dependent on the accuracy of the value for the 
forward rate constant.   
 
 
 
 
 
Figure 28. History plot of the concentration of Ab-Ag complex
formation at kf = 1x10
4 m
-1s
-1 and high diffusivity at the tumor
middle. Total simulation time was almost 6.5 days.   
  11Figure 29.  Presence of Ab-Ag complex in the tumor using the
origina
Figure 30.  Presence of Ab-Ag complex throughout the tumor
using a reduced  kf. value. Again, this contour shows primarily
the tumor and is also at a later time.  
l kf value. This contour shows a close-up of the tumor
(the quarter circle). 
 
 
Figure 29 shows the presence of bound Ab-Ag complex from the control simulation 
using the initial kf value, while Figure 30 shows the complex forming much deeper in the tumor 
when kf  is reduced and the simulation ran longer. This result was misleading because the 
simulation appeared to end at arbitrary times, but we knew that Ab-Ag complex would form 
throughout the tumor but not in the time frame shown in Figure 29. By comparing a contour with 
a lower kf value at the same time as Figure 29 we could assume that the halting of the simulation 
was the main difference between the simulations, and though the final concentrations and time 
needed to attain them would be different, they would both show complex throughout the tumor 
(Figure 30). Because kf controls the rate of complex formation, when it was reduced the rate of 
binding was similarly affected so the antibody diffused further into the tumor before becoming 
bound.   
 
 
 
  12Applying an exponential decay boundary condition 
Furthermore, to evaluate the sensitivity of our model we applied an exponential decay to 
the source of antibody diffusing into the tissue to simulate the clearing of the antibody by the 
lymphatic system.  This would also simulate the movement of a finite dosage of antibody from 
outside the tissue, into the tissue, and deep into the tumor, as shown in Figure 32. Figure 31, 
which shows the contour at time-step 1 confirms that the behavior of the antibody diffusion 
process started out the same as when the external tissue surface was kept at a constant value.     
 
Figure 31. Antibody concentration at the start of a diffusion
simulation including exponential decay of the antibody
boundary condition on the tissue surface. 
Figure 32. Antibody concentration at end of a simulation
including an exponential decay term. Note the difference in
actual concentration values (rather than just color differences)
as compared to Figures 5 or 9.     
 
The result of the exponential decay of antibody near the surface of the modeled tissue is 
shown by the light band near the surface of Figure 32.  The consequence of this would be an 
overall reduction in the total antibody concentration in the tissue and the tumor, and thus the 
complex formation. This would render the treatment less effective considering the dosage 
reaching the tumor would be diminished.     
 
 
  13Using different meshes to test convergence 
Finally, we examined the effect of varying the tumor portion of our mesh. First we 
returned to our original, rough mesh of the tumor, Figure 33 (compare to control mesh in Figures 
2 and 3) but this produced unsatisfactory solutions for the Ab-Ag complex contour in Figure 34 
as compared to Figure 29.   
Figure 33.  Rougher, original tumor mesh with node numbers. Figure 34. Non-uniform results obtained for the complex
formation in the tumor region due to the poor mesh design in
Figure 33. 
 
    
 
Our next effort involved refining our mesh 
further than our control mesh displayed in 
Figure 2.  This new mesh (Figure 35) required 
considerably more calculation time and 
showed little change in the final results 
(Figure 36) which still supported our earlier 
findings. This mesh did show a slightly 
thinner boundary layer of complex formation, 
but the pattern of a high concentration 
Figure 35.  Refined tumor mesh with an increased number of
nodes. Calculations took considerably longer making the mesh,
which gave similar results, unnecessary. 
  14surrounded on either side by a lower 
concentration was still there due to the 
interpolation between mesh nodes regardless 
of how small we made them. Thus, 
considering the additional time required for 
calculation to arrive at the same result, we 
opted not to use the refined mesh.   
Figure 36. Contour plot of complex concentration in the tumor
region at the end of a simulation using the refined mesh with a
higher number of nodes.   
 
Conclusions and Design Recommendations 
Design Recommendations: 
A search of recent radioimmunotherapy (RIT) literature
2 shows that the most recent 
successful RIT of metastatic malignant melanoma used 
188Re (rhenium) chelated to monoclonal 
antibody 6D2.  Hence, the antibody (species 1 in our model) that we will consider is 6D2.  188-
Rhenium (
188Re) is a high energy beta-emitting radionuclide with a half life of 17 hours.  The 
RIT study using 
188Re-6D2 was done using mice, so the radioactivity used in that study would 
not be sufficient for humans.  In that experiment, an injection of 1 to 2 mCi (millicuries, a 
measure of radioactivity) was used. 
In a study of radiotherapy of malignant melanoma of the skin using beta-emitting 
radionuclides
3, Lee et al used a radioactive patch to kill tumor cells in the skin.  Although our 
therapy targets melanoma that has metastasized and begun to grow at a secondary tumor site, we 
can learn from how much radioactivity (in mCi) was necessary to kill melanoma cells in the skin 
in human trials.  The study found that a patch containing 7.4-27 mCi of 
166Ho (holmium) applied 
  15above the tumor site for 30 min to 1 hour would destroy the tumor after about one week (human 
skin is about 3 mm thick).  A necessary simplification to translate these data to our model is that 
during the 30 min to 1 hour that the patch is applied, the radioactive decay (loss of activity) is 
negligible since the half life of 
166Ho is 1.117 days
4. 
In order to be conservative, we made the assumption that 27 mCi applied over 1 hour can 
penetrate 3 mm of tissue (the thickness of the skin) and cause complete tumor death (observed 
after one week).  Assuming that the tumor in this case is 3 mm in depth, length, and width, the 
tumor’s volume is 27 mm
3.  Thus, 1 (mCi*hr)/(mm
3) would be appropriate for therapy of our 
tumor.  Since the volume of our tumor is (4/3)π(0.15 mm)
3 = 0.0141 mm
3, 14.1 µCi*hr is the 
goal for our tumor treated with a beta-emitter with a similar energy to 
166Ho (this assumes a 
direct relationship between tumor size and the amount of radioactivity needed to kill it). 
However, 
188Re is a higher energy beta-emitter (Emax = 2.12 MeV)
2 than 
166Ho (Emax = 0.264 
MeV)
4. Additionally, 
188R deposits 90% of its beta energy within a 2.1 mm radius of tissue
5, so it 
is more effective than 
166Ho for destroying an average sized metastatic melanoma tumor in its 
early stages.  It has also been reported that 
188Re’s beta emissions can penetrate up to one third of 
an inch
 (8.5 mm), which also makes it suitable for the treatment of larger tumors
6.  Since 
188Re 
has 8 times the beta-emission energy of 
166Ho, 1.76 µCi*hr is the goal for the destruction of our 
tumor. 
  Since the half-life of 
188Re is 17 hours, before we can find out how much radioactivity is 
getting into the tumor, radioactive decay must be taken into account.  The half-life equation is:  
A = A0e
-0.693(t/t1/2), where A is the amount of active 
188Re, A0 is the initial amount of active 
188Re, 
t is the elapsed time since A0, and t1/2 is the half life of 
188Re.  Figure 12 (page 10) represents the 
formation of complex over time 0.075 mm from the center of the tumor for the high antibody 
  16diffusivity model. As the plot shows, complex is formed primarily between hours 5 and 7 (from 
about 0 to about 9 times the original surface concentration of antibody, respectively), and then 
stays bound at this concentration (since kf is much greater than kr). To get the value for 
radioactivity*time (µCi*hr), we used a series of calculations in Microsoft Excel. First, we found 
the radioactivity as a percent of the original for times from t = 5 - 50 hr (see Table 1) from the 
half-life equation shown above.  Then, we varied the injected radioactivity (see Table 2), found 
the blood concentration of radioactivity (based on an average of 5 liters of blood per person), and 
calculated the radioactivity*time for each time increment. Next we found the sum for all of the 
time increments. Radioactivity*time data, with varying injected radioactivity, is shown in Table 
2. 
  Based on our radioactivity*time goal for the tumor of 1.76 µCi*hr, the ideal injected 
radioactivity to destroy the tumor would be 65 mCi, as shown in Table 2.  It has been reported 
that 100 µg of 
188Re-6D2 has 1.5 mCi of radioactivity at the initial time
2.  Therefore, the amount 
of 
188Re-6D2 that should be injected is 4.33 mg, which can be suspended in a normal saline 
solution.  Our recommendation is that there should be a human clinical trial of this therapy on 
patients with metastatic melanoma with multiple secondary tumor sites.  Our research should 
provide insight and offer a starting point for the determination of how much radioactivity to use 
in these clinical trials. 
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Table 1: Calculated radioactivity*time in the tumor based on the radioactive decay of 
188Re (t1/2 = 17 hours). 
This table shows a sample calculation for an injected radioactivity of 70 mCi. 
Time 
(hr) 
Complex (species 3) 
concentration (times 
greater than surface 
concentration) 
Radioactivity (% 
of original) 
Radioactivity 
in tumor 
(µCi/mm
3) 
(Radioactivity) 
*(Time Inc.) 
(µCi)*(hr) 
5 0  0.816    
7 9  0.752 0.095 0.074
10 9  0.665 0.084 0.419
15 9  0.543 0.068 0.342
20 9  0.443 0.056 0.279
25 9  0.361 0.045 0.227
30 9  0.294 0.037 0.185
35 9  0.240 0.030 0.151
40 9  0.196 0.025 0.123
45 9  0.160 0.020 0.101
50 9  0.130 0.016 0.082
         Total  1.984
 
 
Table 2: Radioactivity*time in the tumor for varying injected 
radioactivity for a person with a blood volume of 5 L. 
 
 
 
As shown in the results section, the efficacy 
of the treatment is limited not by the binding 
of the antibody to the antigen, but by the 
diffusion of the antibody through the tissue 
and tumor.  From this general observation, 
we recommend that when comparing 
different antibodies for use in RIT, the 
diffusivity of the antibody should be 
seriously considered.  Since diffusivity values of most antibodies in different media have not 
been reported, an estimate of the relative diffusivity values of antibodies can be obtained by the 
molecular weight of the antibody.  Since molecular weight is inversely proportional to 
diffusivity, a lower molecular weight antibody is preferable for RIT.  Further studies in FIDAP 
Injected 
Radioactivity 
(mCi) 
Initial Blood 
Radioactivity 
(µCi/mm
3) 
Radioactivity*Time 
(µCi)*(hr) 
5 0.001 0.142
10 0.002 0.283
15 0.003 0.425
20 0.004 0.567
25 0.005 0.709
30 0.006 0.850
35 0.007 0.992
40 0.008 1.130
45 0.009 1.280
50 0.010 1.420
55 0.011 1.560
60 0.012 1.700
65 0.013 1.840
70 0.014 1.980
  18could be used to compare two prospective antibodies for RIT.  Given an antibody’s molecular 
weight (which would be used to estimate the diffusivity) and Michaelis-Menten rate constants 
for binding with the antigen, FIDAP could run a simulation to see how fast diffusion and binding 
occur, thus estimating the requirements of a treatment. 
Computer-aided engineering promises to be one of the key investigative techniques of the 
21
st century.  With advancement in computer technology, running simulations on a computer is 
now easier, less expensive (less materials, space, and time are required), and more accurate.  
Changes to the problem definition are easily made, increasing our capability to reverse engineer 
a specific desired outcome.  In the case of clinical trials, computer modeling decreases the risk of 
adverse effects especially in human experimentation while reducing the number of trials that 
need to be conducted.  Computer modeling should be the first step in any investigations and, 
when combined with well designed experiments, promises to increase the pace and accuracy of 
current scientific investigations. 
 
  19Appendix A: Non-Dimensionalization 
Our first attempt at simulating this model in FIDAP did not work correctly because some of the 
numbers were very small, resulting in computational error.  In order to get around this problem 
we non-dimensionalized all the terms and equations that were used in FIDAP relative to the 
diffusivity value of the antibody in our tumor.  This allowed us to enter larger numbers for 
diffusivity into FIDAP, eliminating our computational error.  We divided all of our terms by 
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Time also became non-dimensional, however we left the concentrations at their actual values of 
100 and 1000 nM for the antibody and antigen, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  20Appendix B: Model Parameters and Constants 
 
 
 
Plasma Kinetics 
 
CAo      100  nM 
α1      0.27 
α2      0.73 
λ1      1.94  x10
-4 s
-1 
λ2      7.43  x10
-6 s
-1
 
Tissue Properties
 
Dtum      6.3  x10
-9, 2.0 x10
-7 cm
2/s 
Dtis      3.2  x10
-9, 1.0 x10
-7 cm
2/s 
Rtum      0.015  cm 
Rtis      0.15  cm 
so      0.0001  cm  =  1  µm 
 
Reaction Kinetics
 
kf      1.0  x10
4M
-1s
-1 
kr      1.0  x10
-6, 1.0 x10
-5 s
-1 
n       2  
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Figures 13, 14, 15. Contour plots at timestep 1 of antibody concentration with initial antigen concentrations of 10, 100, and 
10,000  M, respectively.  ely.  n    
   
   
   
   
   
   
   
   
   
   
   
   
 
 
 
 
 
   
 
Figures 16, 17, 18. Contour plots at the final time (each contour has a different final time) of antibody concentration with initial 
antigen concentrations of 10, 100, and 10,000 nM, respectively. Plots at similar times show the same contour but with different 
concentrations. We found that the higher the antigen concentration, the longer the simulation was able to run. 
   
   
   
   
   
   
   
   
   
   
   
 
 
 
   
 
Figures 19, 20, 21. History plots at the tumor surface for differing initial antigen concentrations of 10, 100, and 10,000 nM, 
respectively. Note the difference in time that it took the antigen to deplete as the complex was formed; higher initial concentration 
meant more time for total depletion. 
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Figures 22, 23, 24. History plots at the tumor surface showing the Ab-Ag complex formation at different initial antigen 
concentrations (10, 100, 10,000 nM, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 25, 26, 27. History plots at the tumor middle showing the Ab-Ag complex formation at different initial antigen 
concentrations (10, 100, 10,000 nM, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  23Appendix D: FIDAP Input Parameters 
 
SIMULATION 
 
  EXECUTION Command: 
  Execution  Mode   NEWJOB 
 
PROBLEM Command: 
 
 Geometry    AXISYMMETRY 
 Flow  regime    INCOMPRESSIBLE 
  Simulation type     TRANSIENT 
 Flow  type    LAMINAR 
 Convective  term   LINEAR 
 Fluid  type    NEWTONIAN 
 Momentum  Equation   NOMOMENTUM 
 Temperature  dependence  ISOTHERMAL 
 Surface  type    FIXED 
 Structural  solver   NOSTRUCTURAL 
 Elasticity      NOREMESHING 
  Number of phases    SINGLEPHASE 
 Species  Dependence   SPECIES  =  1.0, SPECIES = 2.0, SPECIES = 3.0 
 
Species 1.0, 2.0 and 3.0 corresponds to the antibody, antigen, and the antibody-antigen 
complex respectively. 
 
SOLUTION Command: 
 
  Solution Method    Successive Substituition (S.S) = 10 
  Relaxation factor    ACCF = 0 
 
TIME INTEGRATION Command: 
 
 Time  Integration   BACKWARD 
  No. Time Steps    NSTEP = 1000 
 Starting  time    TSTART  =  0 
 Ending  time    TEND  =  0.122688 
  Time Increment    DT = 0.000122688 
  Time Stepping Algorithm  FIXED 
  
  24ENTITY 
 
 ENTI (NAME = "tissue", SOLI, SPEC = 1.0, MDIF = "md_tis", SPEC = 2.0, 
       MDIF = "md_ag", SPEC = 3.0, MDIF = "md_com") 
 ENTI (NAME = "tumor", SOLI, SPEC = 1.0, MDIF = "md_tum", MREA = "mr_tum", 
       SPEC = 2.0, MDIF = "md_ag", MREA = "mr_ag", SPEC = 3.0, MDIF = "md_com", 
       MREA = "mr_com") 
 ENTI (NAME = "tummid", PLOT) 
 ENTI (NAME = "tismid", PLOT) 
 ENTI (NAME = "tumaxis", PLOT) 
 ENTI (NAME = "tumsurf", PLOT) 
 ENTI (NAME = "tisaxis", PLOT) 
 ENTI (NAME = "tissurf", PLOT) 
 
PROPERTIES 
 
DIFFUSIVITY 
   
 DIFF (SET = "md_tis", CONS = 2.0) 
 DIFF (SET = "md_tum", CONS = 1.0) 
 DIFF (SET = "md_ag", CONS = 0.100000000000E-98) 
 DIFF (SET = "md_com", CONS = 0.100000000000E-98) 
 
REACTION 
 
 REAC (SET = "mr_tum", CONS, TERM = 2, KINE) 
  -0.7031250000E+20,  0.0000000000E+00,  0.0000000000E+00,  0.1000000000E+01, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.2730000000E+03,  0.7031250000E+02, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.2730000000E+03 
 REAC (SET = "mr_ag", CONS, TERM = 2, KINE) 
  -0.1406250000E+21,  0.0000000000E+00,  0.0000000000E+00,  0.1000000000E+01, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.2730000000E+03,  0.1406250000E+03, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.2730000000E+03 
 REAC (SET = "mr_com", CONS, TERM = 2, KINE) 
   0.7031250000E+20,  0.0000000000E+00,  0.0000000000E+00,  0.1000000000E+01, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.2730000000E+03, -0.7031250000E+02, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.1000000000E+01,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00,  0.0000000000E+00, 
   0.0000000000E+00,  0.2730000000E+03 
 
  25BOUNDARY CONDITIONS 
  
  BCNODE 
  
  BCNO (SPEC = 1.0, ENTI = "tissurf", CONS = 1.0, CURV = 1) 
  BCNO (SPEC = 2.0, ENTI = "tumsurf", ZERO) 
  BCNO (SPEC = 3.0, ENTI = "tumsurf", ZERO) 
  
  BCFLUX 
 
  BCFL (SPEC = 1.0, ENTI = "tummid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 1.0, ENTI = "tismid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 2.0, ENTI = "tummid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 3.0, ENTI = "tummid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 3.0, ENTI = "tismid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 2.0, ENTI = "tismid", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 2.0, ENTI = "tissurf", CONS = 0.000000000000E+00) 
  BCFL (SPEC = 3.0, ENTI = "tissurf", CONS = 0.000000000000E+00) 
 
INITIAL CONDITIONS 
 
  ICNODE 
 
   ICNO (SPEC = 1.0, ZERO, ENTI = "tissue") 
   ICNO (SPEC = 1.0, ZERO, ENTI = "tumor") 
   ICNO (SPEC = 2.0, ZERO, ENTI = "tissue") 
   ICNO (SPEC = 2.0, CONS = 1000.0, ENTI = "tumor") 
   ICNO (SPEC = 3.0, ZERO, ENTI = "tumor") 
   ICNO (SPEC = 3.0, ZERO, ENTI = "tissue") 
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